Provention Bio has dosed the first patients in its Phase Ib/IIa PREVAIL clinical trial of humanised diabody PRV-3279.
PRV-3279 targets the B-cell surface proteins, CD32B and CD79B.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The PREVAIL study comprises a Phase Ib trial in healthy volunteers, followed by a Phase IIa trial in patients with systemic lupus erythematosus (SLE).
During the randomised, double-blind, placebo-controlled, multiple-ascending dose Phase Ia study, the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of PRV-3279 will be evaluated in 16 healthy volunteers.
After completion, the Phase IIa portion of the study will be initiated in Lupus patients.
Provention Bio co-founder and chief scientific officer Francisco Leon said: “PRV-3279 offers an elegant mechanism of action designed to intercept and ameliorate the overactive B cell-driven pathology of lupus and other autoimmune diseases.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We believe that PRV-3279 is uniquely differentiated to allow for rapid inhibition of activated B cells, while sparing non-activated B cells from depletion or inactivation, thereby offering the potential for a more effective yet safer alternative to current B-cell targeted therapies.”
Data from the first part of the study is expected in the first half of next year.
Results from a prior single-ascending dose Phase I study showed that PRV-3279 was well-tolerated.
A single dose of the humanised diabody also demonstrated an inhibitory effect on the immunogenicity of hepatitis A vaccine provided to volunteers at the time of the trial.
Provention is initially developing PRV-3279 for the interception of SLE, a chronic autoimmune disorder characterised by an abnormal overactivation of B cells and subsequent pathologic production of auto-antibodies.
In April, Provention Bio concluded patient enrolment in the Phase IIa PRINCE clinical trial of PRV-6527 for the treatment of patients with moderate-to-severe Crohn’s disease.
